Cargando…
EMT is not required for lung metastasis but contributes to chemoresistance
The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610/ https://www.ncbi.nlm.nih.gov/pubmed/26560033 http://dx.doi.org/10.1038/nature15748 |
_version_ | 1782403183979528192 |
---|---|
author | Fischer, Kari R. Durrans, Anna Lee, Sharrell Sheng, Jianting Li, Fuhai Wong, Stephen Choi, Hyejin El Rayes, Tina Ryu, Seongho Troeger, Juliane Schwabe, Robert F. Vahdat, Linda T. Altorki, Nasser K. Mittal, Vivek Gao, Dingcheng |
author_facet | Fischer, Kari R. Durrans, Anna Lee, Sharrell Sheng, Jianting Li, Fuhai Wong, Stephen Choi, Hyejin El Rayes, Tina Ryu, Seongho Troeger, Juliane Schwabe, Robert F. Vahdat, Linda T. Altorki, Nasser K. Mittal, Vivek Gao, Dingcheng |
author_sort | Fischer, Kari R. |
collection | PubMed |
description | The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We confirmed that within a predominantly epithelial primary tumor, a small portion of tumor cells undergo EMT. Strikingly, lung metastases mainly consisted of non-EMT tumor cells maintaining their epithelial phenotype. Inhibiting EMT by overexpressing miR-200 did not impact lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment due to reduced proliferation, apoptotic tolerance, and elevated expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment. |
format | Online Article Text |
id | pubmed-4662610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-46626102016-05-18 EMT is not required for lung metastasis but contributes to chemoresistance Fischer, Kari R. Durrans, Anna Lee, Sharrell Sheng, Jianting Li, Fuhai Wong, Stephen Choi, Hyejin El Rayes, Tina Ryu, Seongho Troeger, Juliane Schwabe, Robert F. Vahdat, Linda T. Altorki, Nasser K. Mittal, Vivek Gao, Dingcheng Nature Article The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We confirmed that within a predominantly epithelial primary tumor, a small portion of tumor cells undergo EMT. Strikingly, lung metastases mainly consisted of non-EMT tumor cells maintaining their epithelial phenotype. Inhibiting EMT by overexpressing miR-200 did not impact lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment due to reduced proliferation, apoptotic tolerance, and elevated expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment. 2015-11-11 2015-11-26 /pmc/articles/PMC4662610/ /pubmed/26560033 http://dx.doi.org/10.1038/nature15748 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Fischer, Kari R. Durrans, Anna Lee, Sharrell Sheng, Jianting Li, Fuhai Wong, Stephen Choi, Hyejin El Rayes, Tina Ryu, Seongho Troeger, Juliane Schwabe, Robert F. Vahdat, Linda T. Altorki, Nasser K. Mittal, Vivek Gao, Dingcheng EMT is not required for lung metastasis but contributes to chemoresistance |
title | EMT is not required for lung metastasis but contributes to chemoresistance |
title_full | EMT is not required for lung metastasis but contributes to chemoresistance |
title_fullStr | EMT is not required for lung metastasis but contributes to chemoresistance |
title_full_unstemmed | EMT is not required for lung metastasis but contributes to chemoresistance |
title_short | EMT is not required for lung metastasis but contributes to chemoresistance |
title_sort | emt is not required for lung metastasis but contributes to chemoresistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610/ https://www.ncbi.nlm.nih.gov/pubmed/26560033 http://dx.doi.org/10.1038/nature15748 |
work_keys_str_mv | AT fischerkarir emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT durransanna emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT leesharrell emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT shengjianting emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT lifuhai emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT wongstephen emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT choihyejin emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT elrayestina emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT ryuseongho emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT troegerjuliane emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT schwaberobertf emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT vahdatlindat emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT altorkinasserk emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT mittalvivek emtisnotrequiredforlungmetastasisbutcontributestochemoresistance AT gaodingcheng emtisnotrequiredforlungmetastasisbutcontributestochemoresistance |